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Ming-Gang Liu1,2 and Min Zhuo1,2*Abstract
One major interest in the study of transient receptor potential vanilloid type 1 (TRPV1) in sensory system is that it
may serve as a drug target for treating chronic pain. While the roles of TRPV1 in peripheral nociception and
sensitization have been well documented, less is known about its contribution to pain-related cortical plasticity.
Here, we used 64 multi-electrode array recording to examine the potential role of TRPV1 in two major forms of
synaptic plasticity, long-term potentiation (LTP) and long-term depression (LTD), in the anterior cingulate cortex (ACC).
We found that pharmacological blockade of TRPV1 with either [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]
dioxin-6-yl)acrylamide] (AMG9810, 10 μM) or N-(3-methoxyphenyl)-4-chlorocinnamide (SB366791, 20 μM) failed to affect
LTP induced by strong theta burst stimulation in the ACC of adult mice. Similarly, neither AMG9810 nor SB366791
blocked the cingulate LTD induced by low-frequency stimulation. Analysis of the results from different layers of the
ACC obtained the same conclusions. Spatial distribution of LTP or LTD-showing channels among the ACC network
was also unaltered by the TRPV1 antagonists. Since cortical LTP and LTD in the ACC play critical roles in chronic
pain triggered by inflammation or nerve injury, our findings suggest that TRPV1 may not be a viable target for
treating chronic pain, especially at the cortical level.
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Transient receptor potential vanilloid type 1, Chronic painIntroduction
The transient receptor potential vanilloid type 1 (TRPV1)
is known to act as a molecular detector for a wide range
of physical (>42°C temperature) and chemical (low PH,
capsaicin) stimuli in the periphery [1-4]. Pharmacological
blockade or genetic deletion of TRPV1 channel can
produce significant analgesic effects in acute pain as well
as inflammatory pain [5-9]. However, controversy still
exists regarding the role of TRPV1 in chronic neuropathic
pain. While there are some pharmacological data showing
the blockade of neuropathic hypersensitivity by TRPV1
antagonists [10-13], TRPV1 knockout mice exhibited no
change in mechanical allodynia or thermal hyperalgesia
following peripheral nerve injury [5,7].* Correspondence: min.zhuo@utoronto.ca
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unless otherwise stated.In addition to its distribution in primary sensory
neurons, TRPV1 has also been found in many regions
of the brain [14-19, also see Table 1]. Neurophysiological
and pharmacological studies demonstrate that TRPV1 is
important for certain forms of synaptic plasticity, such as
long-term potentiation (LTP) and long-term depression
(LTD), in different central synapses [20, also see Table 2].
For example, LTP in the hippocampus is impaired in the
TRPV1-deficient mice [21-23]. Moreover, TRPV1 receptors
can mediate a presynaptic form of LTD in the hippocampus
[24] and a postsynaptic form of LTD in the dentate gyrus
[25] and nucleus accumbens [26].
It is believed that sensory plasticity taking place in
different levels of the central nervous system is important
for chronic pain [36-39]. In addition to the sensitization
occurring at the level of periphery and spinal cord [40,41],
recent studies demonstrate that cortical plasticity might
also contribute critically to chronic pain [for reviews,
see [38,39,42]. Peripheral tissue or nerve injury triggersl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of previous studies on the distribution of TRPV1 in the brain
Species Methods Brain regions Reference
OB CC HP AMY TH HT PAG LC CB
Rat and human ISH, IHC and RT-PCR Yes Yes Yes Yes Yes Yes Yes Yes Yes [14]
Mouse IHC NT NT Yes NT Yes Yes Yes NT Yes [15]
Rat [3H]RTX binding assay Yes Yes Yes Yes Yes Yes Yes NT Yes [17]
Rat RT-PCR Yes Yes Yes NT Yes Yes Yes NT Yes [18]
Rat RPA Yes Yes Yes Yes NT No NT NT Yes [19]
Rat WB, IHC and IEM Yes Yes Yes NT Yes NT Yes Yes Yes [27]
Rat and human [3H]RTX binding assay NT No NT NT Yes Yes Np Yes No [28]
Monkey [3H]RTX binding assay NT Yes NT NT Yes Yes Yes Yes Yes [29]
Rat IHC NT Yes NT NT NT NT NT NT NT [30]
Notes: AMY, amygdala; CB, cerebellum; CC, cerebral cortex; HP, hippocampus; HT, hypothalamus; IEM, immonoelectronmicroscopy; IHC, immunohistochemistry;
ISH, in situ hybridization; LC, locus coeruleus; NT, not tested; OB, olfactory bulb; PAG, periaqueductal gray; RPA, ribonuclease protection assay; RT-PCR, reverse
transcription-polymerase chain reaction; RTX, resiniferatoxin; TH, thalamus; WB, western blot.
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sion in the anterior cingulate cortex (ACC) [43-47]. Drugs
that block the induction or erasing the maintenance of
cingulate LTP produce analgesic effects in animal pain
models [39,46,48-52]. These plastic changes are in accord-
ance with biochemical studies that reveal upregulation
of LTP-related receptors and molecules, such as NMDA
receptor, AMPA receptor and synaptic vesicle proteins,
in the ACC by various forms of pain [44,51,53-56]. There-
fore, cortical plasticity can be used as a novel endpoint
measurement for screening and evaluating analgesic com-
pounds in translational pain studies [42].
The TRPV1 channel has increasingly been considered
to be a promising therapeutic target for clinical pain treat-
ment, despite reported side effects on body temperature
[57-59]. In animal behavioral tests, both TRPV1 receptor
agonists and antagonists have been tested for the treatment
of inflammatory or neuropathic pain [60,61]. Electrophysio-
logical recordings show the lack of spinal LTP in TRPV1
deficient mice [62]. However, to our knowledge, no report
is available on its contribution to pain-related cortical
plasticity. Here we used a 64-channel multi-electrode dish
(MED64) recording system [63-65] to investigate the effects
of two TRPV1 receptor antagonists, (E)-3-(4-t-Butylphe-
nyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide
(AMG9810) and N-(3-methoxyphenyl)- 4-chlorocinnamide
(SB366791), on the induction of LTP and LTD in the
ACC. Interestingly, we found that neither AMG9810
nor SB366791 had any effect on the synaptic plasticity
in the adult mouse ACC.
Materials and methods
Animals
The experiments were carried out on male C57BL/6 mice
(7–10 week old, Charles River, Quebec, Canada). All ani-
mals were fed in groups of three per cage under standard
laboratory conditions (12 h light/12 h dark, temperature22-26°C, air humidity 55-60%) with ad libitum water and
mice chow. The experimental procedures were approved
by the Institutional Animal Care and Use Committee of
The University of Toronto. The number of animals used
and their suffering were greatly minimized.
Drugs
All drugs were purchased from Tocris Cookson (Bristol,
UK). Both AMG9810 and SB366791 were dissolved in
dimethyl sulfoxide (DMSO) as stock solutions and were
diluted to the final desired concentration in the artificial
cerebrospinal fluid (ACSF) before immediate use. The
selectivity of the two drugs against TRPV1 has been
demonstrated previously [66,67]. The concentration of
DMSO in the ACSF was maintained at <0.1%. For the
LTP experiment, the drugs were applied in a bath solution
from 20 min before conditioning stimuli until 20 min after
LTP induction. For the LTD experiment, both agents were
bath applied 25 min prior to and during the LTD induc-
tion. None of the above drugs affected basal synaptic
transmission in the ACC.
Slice preparation
The general procedures for making the ACC slices are
similar to those described previously [46,63,68]. Briefly,
mice were anesthetized with gaseous isoflurane and
decapitated. The whole brain was rapidly removed and
immersed into a cold bath of oxygenated (equilibrated
with 95% O2 and 5% CO2) ACSF containing (in mM):
NaCl 124, KCl 2.5, NaH2PO4 1.0, MgSO4 1, CaCl2 2,
NaHCO3 25 and glucose 10, pH 7.35-7.45. After cooling
for 1–2 min, appropriate portions of the brain were then
trimmed and the remaining brain block was glued onto the
ice-cold stage of a vibrating tissue slicer (Leika, VT1000S).
Then three coronal ACC slices (300 μm) were obtained
at the level of corpus callosum connection and trans-
ferred to an incubation chamber continuously perfused
Table 2 Summary of previous studies on TRPV1 and synaptic plasticity in the brain
Brain area Species Method Plasticity type Key findings Reference




Hippocampus Rat fEPSP LTP and LTD TRPV1 agonists facilitated LTP but
suppressed LTD induction and thus
antagonized the stress effect on
synaptic plasticity in the CA1 region
[22]
CA1 region
Hippocampus Rat fEPSP LTP and LTD TRPV1 activation facilitates LTP
induction via disinhibition, reduces
DHPG-induced acute depression,




Hippocampus Rat EPSC LTD TRPV1 channels activated by
12-(S)-HPETE mediate a presynaptic




Hippocampus Rat EPSC LTD Calcineurin is required for




Hippocampus Mouse fEPSP and EPSC LTP and LTD Loss of interneuron LTD and
attenuated pyramidal cell LTP in
the TRPV1 knockout mice
[23]
CA1 region
Dentate gyrus Rat and mouse EPSC LTD TRNPV1 channels activated by
anandamide mediate a postsynaptic
form of LTD in dentate granular cells
[25]
Superior colliculus Mouse fEPSP LTD TRPV1 channels mediate LTD in the
developing superior colliculus
[33]
Nucleus accumbens Mouse EPSC LTD TRPV1 channels activated by
endocannabinoid mediate a
postsynaptic form of LTD in medium
spiny neurons of the indirect pathway
[26]
BNST and dorsal striatum Rat fEPSP and EPSC LTD TRPV1 channels activated by anandamide
mediate LTD in the BNST but not dorsal
striatum
[34]
Lateral amygdala Mouse fEPSP LTP TRPV1 agonist affected the LTP in a way that
is dependent on the anesthetic
[35]
ACC Mouse fEPSP LTP and LTD TRPV1 antagonosts had no effect on cingulate
LTP or LTD induction
The present study
Notes: 12-(S)-HPETE, 12(S)-hydroperoxyeicosa-5Z, 8Z, 10E, 14Z-tetraenoic acid; ACC, anterior cingulate cortex; BNST, bed nucleus of the stria terminalis; DHPG,
(RS)-3,5-dihydroxy phenylglycine; EPSC, excitatory postsynaptic current; fEPSP, field excitatory postsynaptic potential; LFS, low-frequency stimulation; LTD,
long-term depression; LTP, long-term potentiation; TRPV1, transient receptor potential vanilloid type 1.
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recover for at least 2 h before any electrophysiological
recording was attempted.
Multi-channel field potential recordings
A commercial 64-channel recording system (MED64,
Panasonic Alpha-Med Sciences, Japan) was used for extra-
cellular field potential recordings in this study. Procedures
for preparation of the MED64 probe and multi-channel
field potential recordings were similar to those described
previously [63-65,68,69]. The MED64 probe had an array
of 64 planar microelectrodes, each 50 × 50 μm in size,
arranged in an 8 × 8 pattern (inter-electrode distance:
150 μm). Before use, the surface of the MED64 probe was
treated with 0.1% polyethyleneimine (Sigma) in 25 mMborate buffer (pH 8.4) overnight at room temperature.
After incubation, one slice was positioned on the MED64
probe in such a way that the ACC area was entirely covered
by the recording dish mounted on the stage of an inverted
microscope (CKX41, Olympus). Once the slice was settled,
a fine mesh anchor (Warner Instruments, Harvard) was
carefully positioned to ensure slice stability during record-
ing. The slice was continuously perfused with oxygenated,
fresh ACSF at the rate of 2–3 ml/min with the aid of a
peristaltic pump (Minipuls 3, Gilson) throughout the
entire experimental period.
After a 10–15 min recovery period, one of the 64 avail-
able planar microelectrodes was selected from the 64-
switch box for stimulation by visual observation through a
charge-coupled device camera (DP70, Olympus) connected
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polar, biphasic constant current pulses (0.1 ms in dur-
ation) generated by the data acquisition software (Mobius,
Panasonic Alpha-Med Sciences) were applied to the deep
layer (layer V-VI) of the ACC slice at 0.008 Hz. The field
excitatory postsynaptic potentials (fEPSPs) evoked at both
superficial layer (layer II-III) and deep layer of the ACC
were amplified by a 64-channel amplifier, displayed on the
monitor screen and stored on the hard disk of a micro-
computer for off-line analysis. Baseline synaptic responses
were first stabilized for at least 20 min before any condi-
tioning stimulation. For LTP induction, a theta burst
stimulation (TBS) protocol (5 bursts at 5 Hz, repeated 5
times at 10 s intervals, four pulses at 100 Hz for each
burst) was given at the stimulation intensity which was
adjusted to elicit 40-60% of the maximal response [46].
For LTD induction, a classical low-frequency stimulation
(LFS) protocol (1 Hz, 900 pulses, with the same intensity
as baseline recording) was used as described previously
[63,65,69]. After TBS or LFS, the test stimulus was repeat-
edly delivered once every 2 min for 1–2 h to monitor the
time course of LTP or LTD.
Data analysis
All multi-channel electrophysiological data were analyzed
off-line by the MED64 Mobius software. For quantifica-
tion of the LTP and LTD data, the initial slope of fEPSPs
was measured by taking the rising phase between 10% and
90% of the peak response, normalized and presented sep-
arately in both superficial and deep layers as a percentage
change from the baseline level. The degree of LTP or LTD
in each experiment was shown as the value obtained at
2 h or 1 h after TBS or LFS, respectively. For comparison
of the LTP/LTD magnitude between different treatments,
the averaged value of the last 10 min of recordings was
compared statistically. Furthermore, the number of acti-
vated channels (over 20% of baseline, i.e. the amplitude
goes over −20 μV) vs. LTP-showing (increased by at least
20% of baseline) or LTD-showing (depressed by at least
15% of baseline) channels was counted and expressed as
the induction ratio of LTP/LTD (number of LTP/LTD-
occurring channels/number of all activated channels ×
100%) [64,65,69]. All data are presented as mean ± S.E.
M. When necessary, the statistical significance was assessed
by two-tailed Student’s t test or Mann–Whitney rank
sum test using the SigmaPlot11.0 software. P < 0.05 was
assumed to be statistically significant.
Results
Pharmacological blockade of TRPV1 with AMG9810 does
not affect LTP induction in the ACC
The important role of TRPV1 in LTP induction in the
hippocampus has been shown in previous work using the
genetically modified mice [21-23]. In the present study,we employed a previously-established 64-channel multi-
electrode array system [64,65,68,69] to examine whether
TRPV1 is equally important for cingulate LTP. After
stabilizing the baseline responses for at least 20 min, we
bath applied AMG9810 (10 μM), a selective TRPV1 antag-
onist [67], for 20 min prior to delivery of TBS to the ACC
slice. The drug was washed out 20 min after TBS and LTP
was monitored for 2 h. One representative 64-channel
recording is illustrated in Figure 1A (before TBS) and
Figure 1B (2 h after TBS) for the AMG9810-treated
group. It could be seen that TBS still induced a long-
lasting potentiation of fEPSP within the ACC network.
Analysis of one single channel (Ch. 30) in the superficial
layer (layer I-III) revealed that the response was potenti-
ated to 153.2% of baseline at 2 h after TBS, with the LTP
magnitude being comparable with the control (Ch. 38,
143.8% of baseline; Figure 1C). The averaged data from 5
superficial channels for each condition is plotted in
Figure 1D (control vs. AMG9810: 162.8% vs. 153.4% of
baseline). Pooled data from 6 slices of 6 mice are pre-
sented in Figure 1E (control: 163.4 ± 5.0% of baseline at
2 h after TBS, n = 6 slices/6 mice, P < 0.001, Paired t-test;
AMG9810: 156.6 ± 5.2% of baseline, n = 6 slices/6 mice,
P < 0.001, Paired t-test).
Similar results were obtained when analyzing the
channels located in the deep layer (layer V-VI) of the
ACC. As shown in Figure 1F, infusion of AMG9810
failed to block the LTP induction (control: 158.8 ± 4.8%
of baseline at 2 h after TBS, n = 5 slices/5 mice, P = 0.002,
Paired t-test; AMG9810: 153.6 ± 6.6% of baseline, n = 6
slices/6 mice, P < 0.001, Paired t-test). Statistical analysis
does not detect any significant difference in the degree
of LTP between control and AMG9810-treated group in
either superficial layer (P = 0.818, Mann–Whitney ran sum
test, Figure 1E) or deep layer of the ACC (P = 0.335,
Unpaired t-test, Figure 1F).
In addition to the long-term recording of LTP across
the extended time scale, 64-channel multisite recordings
in the acute slice preparation can also allow us to perform
spatial analysis of LTP distribution among the cortical
network [64]. Therefore, we next analyzed the effect of
AMG9810 on the spatial properties of LTP in the ACC.
The number of activated channels and LTP-occurring
channels was counted for each slice and then displayed
by plotting a polygonal graph on a grid representing the
8 × 8 electrodes. We used the blue lines to represent the
activated channels and the red lines to denote the LTP-
showing channels as previously described [64]. Figure 2A
and B show the grouped data of the control group (A,
activated map; B, LTP map). We found that LTP cannot
be induced in every channel of the ACC slice. In total,
86 channels (mean ± SEM: 14.3 ± 1.2) exhibited clear
synaptic responses from 6 slices, with 71 channels
(mean ± SEM: 11.8 ± 1.2) undergoing LTP. The remaining
Figure 1 Pharmacological blockade of TRPV1 activation with AMG9810 does not affect the LTP induction in the ACC. (A and B) An
overview of 64-channel multi-electrode array recordings in one AMG9810-treated ACC slice (A: before TBS; B: 2 h after TBS). After stabilizing the
baseline responses for 20 min, AMG9810 (10 μM) was bath applied from 20 min before till 20 min after delivery of TBS to the deep layer. It could
be apparently seen that AMG9810 infusion could not prevent the LTP induction. Red circles indicate the stimulated channel (Ch. 29). Vertical lines
demarcate the different layers in the ACC. (C) Results of one LTP-showing channel (Ch. 38 and Ch. 30) from the superficial layer of one slice for
control and AMG9810-treated group, respectively. (D) Summary of averaged data from 5 superficial layer channels of one slice for both control
and AMG9810-applied group, respectively. (E) Pooled data of the superficial layer of the ACC from 6 slices from 6 mice. (F) Pooled data in the
deep layer of the ACC (n = 5–6 slices/5-6 mice). TBS delivery results in an enduring synaptic potentiation that lasts for at least 2 h, which is not affected
by the presence of AMG9810. Insets in (C and F): representative fEPSP traces at time points indicated by the numbers in the graph. Arrows in (C-F)
denote the starting point of TBS application. Calibrations in (A, C and F): 100 μV, 10 ms. Error bars in (E and F) represent SEM.
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unchanged at the baseline level after TBS. Bath application
of AMG9810 (10 μM) did not affect the activation map nor
the LTP map in the ACC (Figure 2C and D). Totally, 90
channels (mean ± SEM: 15.1 ± 1.2) were activated from 6
slices, and 69 channels (mean ± SEM: 11.6 ± 1.4) underwent
LTP. By calculating the induction ratio of LTP (see
Materials and methods), we did not observe any sig-
nificant difference between control and AMG9810-
treated group (control vs. AMG9810: 82.5 ± 4.4% vs.
76.7 ± 9.9%). Taken together, these findings suggest that
pharmacological blockage of TRPV1 with AMG9810
could not prevent the induction of LTP in the ACC.SB366791, another TRPV1 antagonist, also has no effect
on cingulate LTP induction
To confirm the above results, we performed pharmaco-
logical experiments using SB366791 (20 μM), another
TRPV1 antagonist with high potency and an improved
selectivity profile [66]. Pre-treatment of the ACC slice
with SB366791 failed to produce any blocking effect on
the induction of cingulate LTP in both superficial layer
(156.9 ± 5.1% of baseline at 2 h after TBS, n = 6 slices/6
mice, P < 0.001, paired t-test, Figure 3A) and deep layer
(157.3 ± 4.2% of baseline at 2 h after TBS, n = 6 slices/6
mice, P < 0.001, paired t-test, Figure 3B). Statistical analysis
did not reveal any significant difference in the LTP extent
Figure 2 Spatial analysis of LTP distribution in the ACC. (A and B) Polygonal diagrams of the channels that were activated in the baseline
(blue, A) and that showed LTP (red, B) in 6 slices from 6 mice. Vertical lines denote the specific layers in the ACC slice. Overlapped blue regions
denote frequently activated channels, while overlapped red regions indicate the channels that are most likely to undergo LTP. (C and D) Similar
as (A and B) but with TBS delivered in the presence of AMG9810 (n = 6 slices/6 mice). It is evident that the spatial distribution of LTP-showing
channels is not altered by the TRPV1 antagonism.
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layer, P = 0.070; deep layer, P = 0.671, unpaired t-test). We
also determined the spatial distribution of LTP-occurring
channels in the ACC with the presence of SB366791.
Among the 6 slices analyzed, 108 channels (mean ± SEM:
18.6 ± 1.9) were activated and thus showing typical fEPSP
in the baseline condition, while 84 channels (mean ± SEM:
14.4 ± 1.7) displayed LTP lasting for 2 h, with an induction
ratio being 77.8 ± 7.2%. Thus, application of SB366791
could not alter the magnitude of cingulate LTP either.
Pharmacological blockade of TRPV1 has no effect on LTD
induction in the ACC
Besides LTP, LTD is another important form of synaptic
plasticity in the central nervous system [70,71]. Accumu-
lating evidence has been presented to support the involve-
ment of TRPV1 in various forms of LTD in the brain
[24-26,32,33]. Our previous work has mapped the spatio-
temporal properties of LTD in the ACC of adult mice
[63]. Here, we evaluated the consequence of TRPV1
blockade on the induction probability of ACC LTD. One
typical 64-channel recording of LTD in the presence ofAMG9810 (10 μM) is illustrated in Figure 4A (before LFS)
and Figure 4B (1 h after LFS). Figure 4C and D show one
single channel (Ch. 46, 73.4% of baseline at 1 h after LFS)
data and averaged results of 6 channels in the superficial
layer from one slice (74.6% of baseline), respectively.
Pooled data from a series of similar experiments are sum-
marized in Figure 4E. Bath infusion of AMG9810 had no
effect on the induction of LTD in the ACC (74.7 ± 2.8% of
baseline, n = 6 slices/6 mice, P < 0.001, paired t-test), in
comparison with the control group (73.4 ± 1.8% of base-
line, n = 6 slices/5 mice, P < 0.001, paired t-test, Figure 4F).
The lack of effect of AMG9810 on ACC LTD is also
replicated in the deep layer of the ACC (control: 73.2 ±
1.4% of baseline, n = 6 slices/5 mice, P < 0.001, paired
t-test, Figure 4H; AMG9810: 78.7 ± 1.8% of baseline, n = 6
slices/6 mice, P = 0.001, paired t-test, Figure 4G). The
magnitude and duration of LFS-evoked LTD did not differ
between the two groups (superficial layer: P = 0.878, un-
paired t-test; deep layer: P = 0.065, Mann–Whitney rank
sum test).
Figure 5 demonstrates the spatial distribution maps of
activated channels (A and C) and LTD-showing channels
Figure 3 SB366791 cannot block the induction of LTP in the adult mice ACC. (A) Grouped data from 6 slices of 6 mice for SB366791
(20 μM), showing the normal induction of LTP in the superficial layer. (B) Summarized data in the deep layer (n = 6 slices/6 mice). Sample fEPSP
recordings taken at the times indicated by the corresponding numbers are shown at the top of each plot. Arrows in (A and B) show the starting
point of TBS application. Horizontal bars denote the period of drug delivery. Calibration: 100 μV, 10 ms. Error bars represent SEM. (C and D)
Spatial analysis of the effect of SB366791 on LTP distribution in the ACC. Shown are polygonal graphs of the channels that were activated (blue,
C) and that exhibited LTP (red, D) when TBS was delivered in the presence of SB366791 (n = 6 slices/6 mice). Vertical lines denote the specific
layers in the ACC slice. SB366791 has no effect on the LTP distribution map in the ACC.
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group (C and D). Consistent with our previous publication
[63], LFS could not elicit LTD in every activated channel.
There are 59 LTD-undergoing channels (mean ± SEM:
9.8 ± 0.2) out of 82 fEPSP-showing channels (mean ±
SEM: 13.7 ± 0.8) in the control slices (induction ratio:
72.9 ± 3.4%, n = 6 slices/5 mice). In the AMG9810-
applied slices, 93 channels (mean ± SEM: 15.5 ± 1.3)
were activated, among which 66 channels (mean ±
SEM: 10.9 ± 1.1) exhibited LTD (induction ratio: 71.0 ±
4.0%, n = 6 slices/6 mice).
Finally, we also tested the effect of SB366791 (20 μM)
on LTD induction in the ACC. Delivery of LFS to the
deep layer of the ACC slice still resulted in an enduring
synaptic depression in the presence of SB366791. Specific-
ally, the synaptic responses were depressed to 76.9 ± 3.3%
of baseline (n = 6 slices/6 mice, P < 0.001, paired t-test) for
the superficial layer (Figure 6A) and to 75.4 ± 3.3% (n = 6
slices/6 mice, P < 0.001, paired t-test) of baseline for the
deep layer (Figure 6B) at 1 h after LFS. No significance
was detected in the magnitude of LTD between control
and SB366791-treated group (superficial layer: P = 0.959;
deep layer: P = 0.462; unpaired t-test). Furthermore, the
spatial distribution of LTD-showing channels was unalteredby SB366791 application (induction ratio: 69.6 ± 8.8%, n = 6
slices/6 mice, Figure 6C and D). Combining the data of
AMG9810 and SB366791 together, it could be concluded
that pharmacological blockade of TRPV1 channel activa-
tion cannot block LFS-induced LTD in the ACC.
Discussion
In the present study, we used a 64-chanel multi-electrode
array recording system to investigate the effect of two
TRPV1 antagonists on LTP and LTD in the ACC of adult
mice. Although the role of TRPV1 in synaptic plasticity
has been reported in other brain areas (Table 2), we found
that TRPV1 has no critical involvement in either TBS-
induced LTP or LFS-induced LTD in the ACC.
Distribution of TRPV1 in the brain
Since its first clone and characterization in 1997 [2],
TRPV1 channels have been increasingly recognized to
act as a molecular sensor for a range of noxious stimuli
(proton, heat, and capsaicin) in the periphery [1,4,72].
Modulation of the expression or phosphorylation of TRPV1
in primary sensory neurons is believed to be an important
mechanism underlying the development of thermal hyper-
algesia in inflammatory conditions [8,73-75]. Therefore,
Figure 4 Pharmacological blockade of TRPV1 activation with AMG9810 does not affect the LTD induction in the ACC. (A and B) One
sample of 64-channel recordings of ACC LTD induction in the presence of AMG9810 (10 μM). A, baseline; B, 1 h after LFS. AMG9810 was bath applied
25 min prior to and during the LFS delivery to the deep layer of the ACC slice. It is clearly illustrated that AMG9810 did not block LFS-induced LTD.
Red circles indicate the stimulated channel (Ch. 45). Vertical lines demarcate the different layers in the ACC. (C) Results of one channel (Ch. 46) in the
superficial layer of one ACC slice, showing the induction of LTD despite the presence of AMG9810. (D) Summary of averaged data from 6 superficial
channels of the same slice. (E) Pooled data for the superficial layer from 6 slices from 6 mice. (F) Pooled data for the superficial layer of the ACC from
control group (n = 6 slices/5 mice). (G and H) Summarized data for the deep layer of the ACC from control (H, n = 6 slices/5 mice) and AMG9810-treated
(G, n = 6 slices/6 mice) group. Application of AMG9810 did not affect the induction of LTD in any layer of the ACC. Insets in (C, F, G and H): representative
fEPSP traces at time points indicated by the numbers in the graph. Horizontal bars in (C-H) denote the period of LFS or drug application as indicated.
Calibrations in (A, C, F, G and H): 100 μV, 10 ms. Error bars in (E-H) represent SEM.
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resulted in significant analgesic or anti-hyperalgesic effects
in the preclinical research [5,6,11-13,67]. However, mostof these previous studies have focused on the role of
TRPV1 in pain processing at peripheral and spinal levels,
with much less emphasis placed on the supraspinal or
Figure 5 Spatial analysis of LTD distribution in the ACC. (A and B) Polygonal diagrams of the channels that were activated in the baseline
(blue, A) and that showed LTD (red, B) in 6 slices from 5 mice. Vertical lines denote the specific layers in the ACC slice. Overlapped blue regions
denote frequently activated channels, while overlapped red regions indicate the channels that are most likely to undergo LTD. (C and D) Similar
as (A and B) but with LFS delivered in the presence of AMG9810 (n = 6 slices/6 mice). It is evident that the spatial distribution of LTD-showing
channels is not altered by the TRPV1 antagonism.
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http://www.molecularbrain.com/content/7/1/27cortical level [59,76-78]. One of the major reasons for this
phenomenon might be due to the early report showing
the failure to detect TRPV1 mRNA or protein in the brain
[1,2,27]. Nevertheless, a growing number of reports have
indicated that TRPV1 is widely distributed in the central
nervous system, covering a broad array of pain-related
brain areas, such as somatosensory cortex, insular cortex,
hippocampus, amygdala, thalamus and periaqueductal
gray [14-17,28-30, Table 1]. In particular, it has also been
shown to be expressed in the ACC [16,17,79], one of the
most critical forebrain regions contributing to the pain
perception [39,80,81]. Moreover, the brain function of
TRPV1 has been gradually discovered, including control
of body temperature, blood pressure, emesis, locomotion,
anxiety and pain modulation [16]. There is also substantial
evidence suggesting that TRPV1 mediates certain forms of
synaptic plasticity in multiple brain regions [20, see below
for details]. Taken together, all of the above descriptions
highlight the importance of extending the TRPV1 research
from periphery to the central nervous system.
TRPV1 and LTP
As mentioned above, one of the emerging roles of TRPV1
in the brain is to mediate or facilitate LTP induction in thehippocampus (Table 2). Previous genetic studies demon-
strated an attenuated pyramidal cell LTP in hippocampal
CA1 region in the TRPV1 knock-out mice compared to
the wild-type littermates [21-23]. This reduced LTP is
thought to underlie the behavioral impairments in con-
ditioned/cued fear memory, spatial memory and stress
sensitization revealed in the TRPV1 deficient mice [21,22].
In addition, pharmacological activation of TRPV1 receptor
by capsaicin or resiniferatoxin has been shown to facilitate
the CA1 LTP induction by high-frequency stimulation
and thus effectively prevent the blocking effect of stress
on LTP in the hippocampus [22]. TBS-induced LTP could
also be enhanced by TRPV1 agonists, which involves the
GABAergic system in the hippocampal circuitry [31]. In
contrast to the data in the hippocampus, the present re-
sults showed that pharmacological blockade of TRPV1
with either AMG9810 or SB366791 failed to affect the in-
duction probability and magnitude of LTP in the ACC
(Figures 1 and 3). The spatial distribution of LTP-showing
channels among the ACC network was also unaltered by
bath application of the TRPV1 antagonist (Figures 2 and 3),
suggesting no critical involvement of TRPV1 in cingulate
LTP. These negative results are likely not due to the insuffi-
cient drug dose applied during the experiment, because
Figure 6 SB366791 cannot block the induction of LTD in the adult mice ACC. (A) Grouped data from 6 slices of 6 mice for SB366791
(20 μM), showing the normal induction of LTD in the superficial layer. (B) Summarized data in the deep layer (n = 6 slices/6 mice). Sample fEPSP
recordings taken at the times indicated by the corresponding numbers are shown at the top of each plot. Horizontal bars denote the period of
LFS or drug application as indicated. Calibration: 100 μV, 10 ms. Error bars represent SEM. (C and D) Spatial analysis of the effect of SB366791 on
LTD distribution in the ACC. Shown are polygonal graphs of the channels that were activated (blue, C) and that exhibited LTD (red, D) when LFS
was delivered in the presence of SB366791 (n = 6 slices/6 mice). Vertical lines denote the specific layers in the ACC slice. SB366791 has no effect
on the LTD distribution map in the ACC.
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the drug got the positive results in vitro [22,25,26,35,82].
Instead, these data indicate that endogenous activation of
TRPV1 is not important for TBS-induced LTP in the ACC.
TRPV1 and LTD
In addition to LTP, evidence has also been provided to
support the involvement of TPRV1 in various forms of
LTD induction in the brain (Table 2). For example, TRPV1
can mediate a presynaptic form of LTD at glutamatergic
synapses on hippocampal GABAergic interneurons, as
revealed by both pharmacological and genetic approaches
in both rats and mice [23,24,32]. On the other hand,
treatment with TRPV1 agonists suppressed low-frequency
stimulation-evoked LTD as well as (RS)-3,5-dihydroxyphe-
nyl-glycine-induced acute depression in the CA1 region
[22,31]. Apart from the hippocampus, TRPV1 activation
by endocannabinoid contributes to the induction of a
postsynaptic form of LTD in either dentate gyrus [25] or
nucleus accumbens [26] or bed nucleus of the stria termi-
nalis [34]. Intriguingly, we did not observe any blockade of
LFS-evoked LTD by AMG9810 or SB366791 in the ACC
slice of adult mice in the present study (Figures 4 and 6).
Consistently, spatial network analysis failed to detect anydifference in the LTD distribution map between control
and drug-applied group (Figures 5 and 6). The reasons for
the discrepancy are not clear but might be attributable to
differences in the recording method, the specific TRPV1-
targeting drug used and/or the brain regions studied.
Overall, it seems likely that TRPV1 channel is not in-
volved in either LTP or LTD induction in the ACC.
However, previous studies have shown the expression
of TRPV1 protein in the ACC via [3H] RTX binding assay
[17] or immunohistochemistry [79]. Thus, TRPV1 channel
may have a not yet identified role in the ACC other than
mediating certain forms of synaptic plasticity.
TRPV1 and chronic pain
As introduced above, the TRPV1 receptor is now consid-
ered a promising target for the development of novel anal-
gesics with clinical potentials [57-61]. However, compared
to the primary sensory neurons and spinal cord, much less
is known about the function of TRPV1 in the brain
[16,83]. The ACC is well known to be an important fore-
brain area that is critical for pain perception, modulation
and chronic pain processing [80,84-88]. Our previous
series of work have obtained the conclusion that synaptic
plasticity in the ACC, like LTP and LTD, can serve as
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current study, we cannot detect any significant effect of
TRPV1 antagonism on the induction of LTP or LTD in
the ACC. This result indicates that TRPV1 antagonists
could not block pain-related cortical plasticity. Consistent
with the present study, the early work in TRPV1 knock-out
mice showed the impaired behavioral responses to noxious
heat stimuli and reduced acute inflammatory thermal
hyperalgesia, but without any alteration in mechanical
allodynia and neuropathic pain hypersensitivity [5,6].
Therefore, it is unlikely that any novel TRPV1 antagonists
will be effective in the treatment of chronic inflammatory
or neuropathic pain. Moreover, treating chronic pain pa-
tients with TRPV1 antagonists may produce untoward
side effects, such as hyperthermia, increased susceptibility
to cardiovascular diseases, etc. [60,61,89]. Possible side
effects on cognitive and executive functions remain to be
investigated, considering the important roles of TRPV1
in hippocampal plasticity as well as other regions of
the brain.
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